-
Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome. Brain. 2021 06 22; 144(5):e44.
Foschi M, D'Anna L, Abdelhak A, Mayer B, Tumani H, Otto M, Abu-Rumeileh S. PMID: 33822000.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells. 2020 11 25; 9(12).
Robinson T, Abdelhak A, Bose T, Meinl E, Otto M, Zettl UK, Dersch R, Tumani H, Rauer S, Huss A. PMID: 33255854.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCells
-
Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies. Biomedicines. 2020 Aug 28; 8(9).
Huss A, Senel M, Abdelhak A, Mayer B, Kassubek J, Ludolph AC, Otto M, Tumani H. PMID: 32872144.
View in:
PubMed Mentions:
-
Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr; 268(4):1133-1170.
Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. PMID: 32840686.
View in:
PubMed Mentions:
49 Fields:
Translation:
Humans
-
A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course. Front Neurol. 2020; 11:608.
Huss A, Otto M, Senel M, Ludolph AC, Abdelhak A, Tumani H. PMID: 32765393.
View in:
PubMed Mentions:
-
Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study. Contemp Clin Trials Commun. 2020 Jun; 18:100574.
Abdelhak A, Huss A, Stahmann A, Senel M, Krumbholz M, Kowarik MC, Havla J, Kümpfel T, Kleiter I, Wüstinger I, Zettl UK, Schwartz M, Roesler R, Friede T, Ludolph AC, Ziemann U, Tumani H. PMID: 32478196.
View in:
PubMed Mentions:
-
Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? Front Neurol. 2019; 10:280.
Abdelhak A, Hottenrott T, Morenas-Rodríguez E, Suárez-Calvet M, Zettl UK, Haass C, Meuth SG, Rauer S, Otto M, Tumani H, Huss A. PMID: 30972011.
View in:
PubMed Mentions:
-
Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018 10 04; 8(1):14798.
Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. PMID: 30287870.
View in:
PubMed Mentions:
33 Fields:
Translation:
Humans
-
Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients. Ann Neurol. 2018 05; 83(5):1032-1036.
Huss A, Abdelhak A, Halbgebauer S, Mayer B, Senel M, Otto M, Tumani H. PMID: 29665046.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation. 2018 Mar 19; 15(1):88.
Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B. PMID: 29554927.
View in:
PubMed Mentions:
18 Fields:
Translation:
HumansCells
-
CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. PLoS One. 2017; 12(8):e0182647.
Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H. PMID: 28797088.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Primary Progressive Multiple Sclerosis: Putting Together the Puzzle. Front Neurol. 2017; 8:234.
Abdelhak A, Weber MS, Tumani H. PMID: 28620346.
View in:
PubMed Mentions:
-
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? Int J Mol Sci. 2015 Jul 31; 16(8):17565-88.
Abdelhak A, Junker A, Brettschneider J, Kassubek J, Ludolph AC, Otto M, Tumani H. PMID: 26263977.
View in:
PubMed Mentions:
11 Fields:
Translation:
HumansCells